389 Background: This retrospective register study assessed OS in all mRCC patients in
Sweden diagnosed before (2000–2005) and after (2006–2008) the introduction of targeted …

Background This retrospective study investigated overall survival (OS) and factors
influencing OS in Swedish patients with metastatic renal cell carcinoma (mRCC) during the …

Background: This retrospective register study assessed overall survival (OS) and influential
factors on OS in Swedish renal cell carcinoma (RCC) patients. Methods: Using three merged …

BACKGROUND. The majority of metastatic renal cell carcinoma (mRCC) clinical trials that
examined targeted agents used progression‐free survival (PFS) as the primary endpoint …

e15586 Background: The main therapy of mRCC before the era of targeted agents was
immunotherapy with interferon-alfa (INFa) or interleukin-2. Current therapies include various …

Purpose: In advanced stage renal cell cancer (RCC), overall survival (OS) of patients has
been prolonged due to targeted therapies. To date, there are several prognostic risk models …

413 Background: The RENal COMParison (RENCOMP) study showed a significant
improvement in OS for Swedish patients diagnosed with renal cell carcinoma (RCC) and …

Background This population-wide retrospective, non-interventional registry study assessed
changes in overall survival (OS) and factors influencing OS in Norwegian patients with renal …

Aim To evaluate the implementation of targeted therapy on overall survival (OS) in a
complete national cohort of patients with metastatic renal cell carcinoma (mRCC). Methods …

20 Background: The results of the 5-year overall survival (OS) in patients with metastatic
renal cell carcinoma (mRCC) has been reported rarely. The aim of the RENSUR5 registry …